Precede Biosciences is a biotechnology company that provides a blood-based approach to reveal disease-defining transcriptional biology.
Precede Biosciences has raised $63.5M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Precede Biosciences's investors include OUP (Osage University Partners), Illumina Ventures, 5AM Ventures, Bristol-Myers Squibb, Lilly Asia Ventures.
Precede Biosciences is headquartered in Boston, United States.
Precede Biosciences is a biotechnology company that provides a blood-based approach to reveal disease-defining transcriptional biology.
Precede Biosciences is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Precede Biosciences — Funding & Investors." VCBacked, January 12, 2026, https://www.vcbacked.co/company/precede-biosciences. Accessed July 21, 2026.
VCBacked. (2026). Precede Biosciences — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/precede-biosciences
{{cite web |title=Precede Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/precede-biosciences |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated